Source File

Are GLP-1s the First Longevity Drugs? Every Proven (and Promising) Benefit, Ranked by Evidence

Six FDA-approved indications. Addiction reduction across every major substance. A 45% drop in Alzheimer's risk. Here is every GLP-1 benefit, ranked by the strength of the evidence behind it.

May 19, 2026

The Scorecard No One Expected

In November 2025, Nature Biotechnology published an editorial asking a provocative question: are GLP-1 receptor agonists the first true longevity drugs? At the time, it read as hyperbole. Six months later, the evidence has stacked so high that the question isn't whether GLP-1s do more than weight loss — it's whether there's a major disease category they don't touch.

Here's every confirmed and emerging benefit, organized by strength of evidence, with the actual data behind each one.

Tier 1: FDA-Approved Indications (Gold Standard)

These aren't speculative. These are uses the FDA has formally evaluated and approved based on large-scale randomized controlled trials.

Indication	Drug(s) Approved	Key Trial	Key Result
Type 2 Diabetes	Ozempic, Mounjaro, Rybelsus	SUSTAIN, SURPASS	HbA1c reduction up to 2.1%
Chronic Weight Management	Wegovy, Zepbound, Foundayo	STEP, SURMOUNT, ATTAIN	15–21% body weight loss
Cardiovascular Risk Reduction	Wegovy	SELECT	20% reduction in MACE events
Chronic Kidney Disease (with T2D)	Ozempic	FLOW	24% reduction in kidney disease progression
Obstructive Sleep Apnea	Zepbound	SURMOUNT-OSA	~50% reduction in AHI events
Metabolic Liver Disease (MASH)	Wegovy	ESSENCE	Steatohepatitis resolution without fibrosis worsening

6 Distinct FDA-approved therapeutic areas for GLP-1 medications as of May 2026 — more than any other drug class approved in the last decade for a single mechanism of action.

Tier 2: Strong Clinical Evidence (Major Trials Completed or Underway)

Condition	Evidence	What the Data Shows
Heart Failure (HFpEF)	STEP-HFpEF trial	Semaglutide improved symptoms, exercise capacity, and reduced weight in heart failure patients with preserved ejection fraction
Substance Use Disorders	600K-patient VA study (2026)	15–25% lower risk across opioids, cocaine, nicotine, alcohol, and cannabis
Peripheral Artery Disease	Wegovy FDA expansion	Reduced risk of PAD events in the SELECT trial
Alzheimer's Risk Reduction	Meta-analysis of 160K+ patients	45% lower risk of dementia in GLP-1 users vs. other diabetes drugs
Colorectal Cancer Risk	2026 ASCO GI Symposium data	GLP-1 users showed reduced colorectal cancer incidence

Tier 3: Emerging & Preclinical (Watch This Space)

Condition	Status	Why It's Interesting
Type 1 Diabetes	Phase 3 trials (Novo + Lilly)	Adjunctive use to insulin — completion expected 2027
Osteoarthritis / Knee Pain	Phase 3 (Lilly, retratrutide)	Weight reduction + potential direct anti-inflammatory effects
Inflammatory Bowel Disease	Phase 3 (tirzepatide + mirikizumab)	Combination therapy for UC and Crohn's — expected 2028
Psoriasis / Psoriatic Arthritis	Phase 3 (tirzepatide + ixekizumab)	Completion expected 1H 2026
Hypertension (with obesity)	Under investigation (orforglipron)	Blood pressure reduction as primary endpoint

The Numbers That Put It In Context

1 in 8 American adults currently on a GLP-1 medication (KFF, 2026). Estimated 30 million people, up from ~4 million in 2020. MM+M

A Nature Medicine review published in January 2026 summarized it this way: GLP-1 medicines improve health through reduction of blood glucose and body weight, by attenuation of inflammation, and via direct activation of receptors in target tissues. The scope of benefit is expanding faster than any drug class in modern pharmaceutical history.

What Failed: Alzheimer's Treatment (Not Prevention)

In December 2025, two large clinical trials (EVOKE and EVOKE+) found that oral semaglutide did not slow Alzheimer's progression in patients who already had the disease. This is an important distinction: GLP-1s appear to reduce the risk of developing dementia, but may not treat it once established. As one researcher put it: "We asked if GLP-1s could treat everything. The answer is no — but the list of what they can do keeps getting longer."

This isn't hype. It's six FDA approvals, dozens of major clinical trials, and the largest real-world dataset ever assembled for a single drug class. Whether that makes GLP-1s "longevity drugs" depends on your definition — but by any clinical measure, nothing else comes close.

Sesame Care

FDA-approved brand-name Wegovy & Zepbound prescriptions

From $175/mo

Visit Provider → Paid link

Found Health

Personalized weight loss programs with ongoing clinical support

From $99/mo (with promo)